Exploring Polθ as a New DDR Target

Time: 4:30 pm
day: Day One

Details:

  • Discovery and preclinical development of first-in-class inhibitors for oncology in a PARP-resistant setting
  • Leveraging synthetic lethality and understanding of the theta-mediated end joining (TMEJ) to determine a validated target
  • Latest from the lab, clinical validation, and future directions
  • Discussing how it will compare to PARP
  • Dissecting how to leverage it as a novel target
  • Combination – who, where, what?

Speakers: